Login to Your Account



Horizon, Centauri form joint venture to move Alphamer technology into oncology

By Cormac Sheridan
Staff Writer

Wednesday, March 2, 2016

DUBLIN – Avvinity Therapeutics Ltd., a newly created joint venture between Horizon Discovery Group plc and start-up firm Centauri Therapeutics Ltd., is getting up to £5.3 million (US$7.4 million) in series A funding to apply Centauri’s Alphamer anti-infectives technology to immuno-oncology indications.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription